Search Results

Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes

Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor

of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic

biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic

lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic

The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure.

This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor translational impact — giving us new ways to think about receptor pharmacology, biased agonism, and therapeutic DrGPCR #Pharmacology #DrugDiscovery #AllostericModulation #Kinetics #AssayDevelopment #EarlyDiscovery #PharmaR lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure.

We hope our research will aid in the development of new therapeutic interventions for the alleviation

embody the multifaceted nature of GPCRs, showcasing their complexity, versatility, and potential for therapeutic

DrGPCR #Pharmacology #DrugDiscovery #AllostericModulation #Kinetics #AssayDevelopment #EarlyDiscovery #PharmaR

Measuring and understanding bias helps design drugs that maximize therapeutic benefits while minimizing See- The Importance of Pharmacologic Assays Lecture 2: Drug Disposition in Physiological Tissues as a Therapeutic Lecture 4: Unconventional GPCR Ligands as Drugs Lecture 5: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic

He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director

She has advanced the use of computational methods to meet the challenges of designing therapeutics with

Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic

His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic

clinical stage company developing next generation immunotherapies, and member of the SAB of Domain Therapeutics

His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

Pharmacology #DrugDiscovery #Biotech #AllostericModulation #Kinetics #AssayDevelopment #EarlyDiscovery #PharmaR

Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics

of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic